Literature DB >> 850080

Dose-response relationship after immunization of volunteers with a new, surface-antigen-adsorbed influenza virus vaccine.

C W Potter, R Jennings, J P Phair, A Clarke, C H Stuart-Harris.   

Abstract

Volunteers (15 per group) were given inoculations of various doses (5-400 international units [IU]) of surface-antigen-adsorbed influenza virus A/Port Chalmers/73 vaccine; this vaccine was prepared from purified virus hemagglutinin and neuraminidase antigens and adsorbed to alhydrogel. The titers of hemagglutination-inhibiting (HAI) and neuraminidase-inhibiting antibodies in serum after immunization showed a clear dose-response relationship. Thus, for volunteers given 400, 100, 25, or 5.0 IU of vaccine, the titers of HAI antibody in serum increased 174-, 32-, 12-, and eightfold, respectively. A similar dose response was observed for production of local neutralizing antibody. Immunization with A/Port Chalmers/73 virus vaccine also induced serum HAI antibody to influenza viruses A/Scotland/74, A/England/72, and A/Hong Kong/68; the increase in titers of antibody to these viruses corresponded directly to the degree of cross-reactivity between the virus tested and the vaccine virus. Four weeks after immunization, all volunteers were challenged with attenuated WRL-105 influenza virus. Evidence of viral infection was found in one, two, and two volunteers in each group of 15 subjects previously immunized with 400, 100, and 25 IU of vaccine, respectively; in six of the 15 volunteers given 5.0 IU of vaccine; and in 10 of 15 control subjects. The results suggest that equivalent immunity was induced in volunteers given greater than or equal to 25 IU of vaccine.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 850080     DOI: 10.1093/infdis/135.3.423

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge.

Authors:  T M Ross; Y Xu; R A Bright; H L Robinson
Journal:  Nat Immunol       Date:  2000-08       Impact factor: 25.606

2.  Production of passive immunity in neonatal ferrets following maternal vaccination with killed influenza A virus vaccines.

Authors:  C Sweet; R A Bird; K Jakeman; D M Coates; H Smith
Journal:  Immunology       Date:  1987-01       Impact factor: 7.397

3.  Reactogenicity and immunogenicity of a surface-antigen-adsorbed influenza virus vaccine in children.

Authors:  L M Eastwood; R Jennings; R D Milner; C W Potter
Journal:  J Clin Pathol       Date:  1979-06       Impact factor: 3.411

4.  Antibody response and persistence in volunteers following immunization with varying dosages of a trivalent surface antigen influenza virus vaccine.

Authors:  R Jennings; T L Smith; A R Mellersh; A Clark; R C Spencer; C W Potter
Journal:  J Hyg (Lond)       Date:  1985-02

5.  The effect of bacterial peptidoglycans on the immune response of hamsters to influenza virus vaccines.

Authors:  C R Crawford; R Jennings; N Bradford; C W Potter
Journal:  Clin Exp Immunol       Date:  1982-06       Impact factor: 4.330

6.  Responses of volunteers to inactivated influenza virus vaccines.

Authors:  R Jennings; C W Potter; P M Massey; B I Duerden; J Martin; A M Bevan
Journal:  J Hyg (Lond)       Date:  1981-02

7.  Synthetic low-toxicity muramyl dipeptide and monophosphoryl lipid A replace Freund complete adjuvant in inducing growth-inhibitory antibodies to the Plasmodium falciparum major merozoite surface protein, gp195.

Authors:  G S Hui; L Q Tam; S P Chang; S E Case; C Hashiro; W A Siddiqui; T Shiba; S Kusumoto; S Kotani
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

8.  A contribution of cellular immunity to protection against influenza in man.

Authors:  R Jennings; R J Fenton; M G McEntegart; C W Potter
Journal:  Med Microbiol Immunol       Date:  1978-11-17       Impact factor: 3.402

9.  A multi-valent vaccine approach that elicits broad immunity within an influenza subtype.

Authors:  Victor C Huber; Paul G Thomas; Jonathan A McCullers
Journal:  Vaccine       Date:  2009-01-07       Impact factor: 3.641

10.  A comparison of live and inactivated influenza A (H1N1) virus vaccines. 2. Long-term immunity.

Authors:  A Clark; C W Potter; R Jennings; J P Nicholl; A F Langrick; G C Schild; J M Wood; D A Tyrrell
Journal:  J Hyg (Lond)       Date:  1983-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.